NYSE : MANE
Veradermics, Incorporated — Financial statements
Healthcare · Biotechnology · United States
Last price 139.69 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.84B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 26.95M | 10.28M | 3.50M | 2.35M |
| Research & Development | 75.82M | 62.06M | 23.28M | 14.97M |
| Operating Expenses | 102.77M | 72.35M | 26.78M | 17.32M |
| Operating Income | -102.77M | -72.35M | -26.78M | -17.32M |
| Interest Expense | -585.00K | -36.00K | ||
| Interest & Investment Income | 8.30M | 1.56M | 481.00K | 870.00K |
| Other Non Operating Income (Expenses) | 1.79M | 790.00K | 394.00K | |
| Pretax Income | -92.68M | -70.00M | -26.49M | -16.49M |
| Net Income | -92.68M | -70.00M | -26.49M | -16.49M |
| Preferred Dividends & Other Adjustments | 11.61M | 13.38M | 815.00K | |
| Net Income to Common | -104.29M | -83.37M | -27.30M | -16.49M |
| Shares Outstanding (Basic) | 16.18M | 744.99K | 736.93K | 736.93K |
| Shares Outstanding (Diluted) | 16.18M | 744.99K | 736.93K | 736.93K |
| EPS (Basic) | -6.44 | -111.91 | -37.05 | -22.38 |
| EPS (Diluted) | -6.44 | -111.91 | -37.05 | -22.38 |
| Free Cash Flow | -78.33M | -71.63M | -23.69M | -13.51M |
| Free Cash Flow Per Share | -4.84 | -96.14 | -32.14 | -18.33 |
| EBIT | -102.77M | -72.35M | -26.78M | -17.32M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 319.33M | 21.77M | 53.08M | 16.30M |
| Short-Term Investments | 500.56M | 120.10M | ||
| Cash & Short-Term Investments | 819.89M | 141.86M | 53.08M | 16.30M |
| Other Receivables | 1.59M | 1.25M | 1.38M | |
| Receivables | 1.59M | 1.25M | 1.38M | |
| Prepaid Expenses | 2.13M | 5.61M | 1.04M | 1.22M |
| Other Current Assets | 1.14M | 3.77M | 38.00K | 46.00K |
| Total Current Assets | 824.75M | 152.49M | 55.53M | 17.56M |
| Property, Plant & Equipment | 989.00K | 125.00K | ||
| Total Assets | 825.74M | 152.62M | 55.53M | 17.56M |
| Accounts Payable | 5.92M | 2.13M | 2.25M | 1.85M |
| Accrued Expenses | 5.39M | 6.98M | 2.47M | 1.20M |
| Other Current Liabilities | 379.00K | 47.00K | ||
| Total Current Liabilities | 11.69M | 9.15M | 4.72M | 3.05M |
| Long-Term Debt | 786.00K | |||
| Long-Term Leases | 428.00K | 4.00K | ||
| Total Liabilities | 12.12M | 9.16M | 4.72M | 3.84M |
| Common Stock | 1.00K | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 989.26M | 2.35M | 750.00K | 500.00K |
| Retained Earnings | -174.16M | -123.42M | -49.23M | -22.74M |
| Comprehensive Income & Other | -1.49M | -1.79M | -3.85M | -894.00K |
| Total Common Equity | 813.61M | -122.86M | -52.33M | -23.14M |
| Shareholders' Equity | 813.61M | 143.46M | 50.82M | 13.72M |
| Total Liabilities & Equity | 825.74M | 152.62M | 55.53M | 17.56M |
| Total Debt | 428.00K | 4.00K | 786.00K | |
| Net Cash (Debt) | 819.47M | 141.86M | 53.08M | 15.51M |
| Net Cash Per Share | 50.63 | 190.42 | 72.03 | 21.05 |
| Filing Date Shares Outstanding | 41.78M | 37.34M | 736.93K | 736.93K |
| Total Common Shares Outstanding | 41.78M | 749.76K | 736.93K | 736.93K |
| Working Capital | 813.05M | 143.34M | 50.82M | 14.51M |
| Book Value Per Share | 19.47 | -163.87 | -71.01 | -31.39 |
| Tangible Book Value | 813.61M | -122.86M | -52.33M | -23.14M |
| Tangible Book Value Per Share | 19.47 | -163.87 | -71.01 | -31.39 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -92.68M | -70.00M | -26.49M | -16.49M |
| Loss (Gain) From Sale of Investments | -389.00K | -556.00K | ||
| Stock-Based Compensation | 9.89M | 1.44M | 250.00K | 206.00K |
| Other Operating Activities | 1.44M | 1.40M | 1.82M | 1.85M |
| Change in Accounts Payable | 5.39M | -122.00K | 646.00K | 1.35M |
| Change in Other Net Operating Assets | -2.37M | -3.76M | 86.00K | -434.00K |
| Operating Cash Flow | -78.30M | -71.60M | -23.69M | -13.51M |
| Capital Expenditures | -26.00K | -24.00K | ||
| Investment in Securities | -473.34M | -118.83M | ||
| Investing Cash Flow | -473.36M | -118.86M | ||
| Long-Term Debt Issued | 8.51M | |||
| Long-Term Debt Repaid | -845.00K | |||
| Net Debt Issued (Repaid) | 7.66M | |||
| Issuance of Common Stock | 683.72M | 156.00K | ||
| Other Financing Activities | 27.67M | -447.00K | -283.00K | -35.00K |
| Financing Cash Flow | 862.40M | 159.14M | 60.48M | 13.89M |
| Net Cash Flow | 310.74M | -31.32M | 36.79M | 385.00K |
| Free Cash Flow | -78.33M | -71.63M | -23.69M | -13.51M |
| Free Cash Flow Per Share | -4.84 | -96.14 | -32.14 | -18.33 |
| Levered Free Cash Flow | -47.55M | -16.37M | ||
| Unlevered Free Cash Flow | -47.55M | -16.01M | ||
| Cash Interest Paid | 95.00K | |||
| Change in Working Capital | 3.02M | -3.89M | 732.00K | 920.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Market Capitalization | 5.40B | |||
| Enterprise Value | 4.58B | |||
| Debt / Equity Ratio | 0.00 | 0.00 | 0.06 | |
| Net Debt / Equity Ratio | -1.01 | -0.99 | -1.04 | -1.13 |
| Net Debt / FCF Ratio | 10.46 | 1.98 | 2.24 | 1.15 |
| Quick Ratio | 70.25 | 15.64 | 11.54 | 5.34 |
| Current Ratio | 70.53 | 16.66 | 11.77 | 5.75 |
| Return on Equity (ROE) | -72.06% | -82.08% | ||
| Return on Assets (ROA) | -43.45% | -45.79% | ||
| Return on Capital Employed (ROCE) | -12.60% | -50.40% | -52.70% | -119.40% |
| Buyback Yield / Dilution | -2,096.15% | -1.09% |